March 13, 2019
Tatiana Karelina, Head of the Alzheimer’s Disease modeling group at InSysBio participated in the Russian TV show «Us and science. Science and us». The theme of the show was Alzheimer’s Disease (AD) and the guests were experts, such a gerontopsychiatrist, a neurologist and a biochemist, representing either optimistic or skeptical positions. Tatiana presented an optimistic point of view and told about AD causes, risk factors, pathological mechanisms and future therapeutic approaches. The video is available on the NTV channel website.
“We are just beginning to research the potential therapies. AD is a multifactorial process, so the potential therapy will be not, for example, an amyloid-targeted particular drug, but it will be a particular combination of such particular drugs. There are many AD triggers, and diverse factors contribute to its pathogenesis, but results are the same: amyloid plaques and neurofibrillary tangles formation and neuron loss. The future treatment will be preventive as well as personalized, so there will be expected many clinical trials investigating various combinatorial therapies,” introduced Tatiana Karelina.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit insysbio.com.
| ← | September 2024 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
|
4
1.
04 Sep 2024 16:07
Now B cells model reflects the current views on the processes
InSysBio launches Immune Response Template (IRT) version 3.6.3. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system
|
5
|
6
|
7
|
8
|
|
9
|
10
1.
10 Sep 2024 18:36
InSysBio team to publish the new article in PSPJournal
The new article "Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms" by Olga Ivanova and Tatiana Karelina was published in PSPJournal at the end of August 2024
|
11
1.
11 Sep 2024 15:25
InSysBio to take part in ACoP 2024
InSysBio announces its participation in the 15th American Conference on Pharmacometrics (ACoP). Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will be a co-chair and speaker of the session "Advancing QSP: From Virtual Patient To Digital Twin". InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #11 and 9 posters in frames of the Conference
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
| ||||||
Thank you for your message! We will get back to you shortly.
